Single dose of Sputnik V triggers strong antibody response: Study

A single dose of the Sputnik V vaccine may be enough to elicit strong antibody response against SARS-CoV-2, the virus that causes COVID-19, in already infected people, a study suggested.

Previous studies have found that two doses of Sputnik V, a vector vaccine produced using a combination of two adenoviruses, results in 92 per cent efficacy against COVID-19 infection.

Adenoviruses are common viruses that cause a range of illness with cold-like symptoms such as fever and sore throat, reported The Indian Express.

The new study, published on Tuesday in the journal Cell Reports Medicine, examined whether a single dose would achieve greater public health benefit than two doses by allowing protection of a larger population more quickly.

“Due to limited vaccine supply and uneven vaccine distribution in many regions of the world, health authorities urgently need data on the immune response to vaccines to optimize vaccination strategies,” said study senior author Andrea Gamarnik of the Fundacion Instituto Leloir-CONICET in Buenos Aires, Argentina.

“The peer-reviewed data we present provide information for guiding public health decisions in light of the current global health emergency,” Gamarnik said.